UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2009-10, Vol.53 (10), p.4385-4392

2009

Volltextzugriff (PDF)

Effect of itraconazole on the pharmacokinetics of faldaprevir in healthy subjects

Pharmazie, 2021-05, Vol.76 (5), p.189-194

2021

Volltextzugriff (PDF)

Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii441-viii441

2018

Volltextzugriff (PDF)

Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing

Physiological genomics, 1999-08, Vol.1 (2), p.51-62

1999

Volltextzugriff (PDF)

P740 PHARMACOKINETICS OF FALDAPREVIR IN HEALTHY SUBJECTS FOLLOWING CO-ADMINISTRATION WITH ITRACONAZOLE

Journal of hepatology, 2014-04, Vol.60 (1), p.S316-S317

2014

Volltextzugriff (PDF)

The Herpes Simplex Virus vhs Protein Induces Endoribonucleolytic Cleavage of Target RNAs in Cell Extracts

Journal of Virology, 1999-09, Vol.73 (9), p.7153-7164

1999

Volltextzugriff (PDF)

HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice

Cancer gene therapy, 2012-12, Vol.19 (12), p.888-898

2012

Volltextzugriff (PDF)

O65 HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN

Journal of hepatology, 2014-04, Vol.60 (1), p.S27-S27

2014

Volltextzugriff (PDF)

697P Open-label, phase I, dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab

Annals of oncology, 2023-10, Vol.34, p.S485-S485

2023

Volltextzugriff (PDF)

Prognosis and survival in patients with gastrointestinal tract carcinoid tumors

Annals of surgery, 1999-06, Vol.229 (6), p.815-21; discussion 822-3

1999

Volltextzugriff (PDF)

Picornavirus Internal Ribosome Entry Site Elements Target RNA Cleavage Events Induced by the Herpes Simplex Virus Virion Host Shutoff Protein

Journal of Virology, 1999-11, Vol.73 (11), p.9222-9231

1999

Volltextzugriff (PDF)

1236 MECHANISMS OF ISOLATED UNCONJUGATED HYPERBILIRUBINEMIA INDUCED BY THE HCV NS3/4A PROTEASE INHIBITOR BI201335

Journal of hepatology, 2011-03, Vol.54, p.S488-S488

2011

Volltextzugriff (PDF)

[36] Herpes simplex virus vhs protein

Methods in Enzymology, 2001, Vol.342, p.440-451

2001

Volltextzugriff (PDF)

542P Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours

Annals of oncology, 2021-09, Vol.32, p.S606-S607

2021

Volltextzugriff (PDF)

Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial

Drugs in R&D, 2011-12, Vol.11 (4), p.295-302

2011

Volltextzugriff (PDF)

1243TiPPhase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir

Clinical infectious diseases, 2014-11, Vol.59 (10), p.1420-1428

2014

Volltextzugriff (PDF)

Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2623-2623

2021

Volltextzugriff (PDF)

Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.212-212

2021

Volltextzugriff (PDF)

An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3054-3054

2020

Volltextzugriff (PDF)

PHARMACOGNOSTICAL, ANTIMICROBIAL AND LAXATIVE STUDY OF SCORZONERA UNDULATA IN LIBYA

International research journal of pharmacy, 2016-11, Vol.4 (4), p.96-99

2016

Volltextzugriff (PDF)

Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3063-3063

2020

Volltextzugriff (PDF)

Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.212-212

2018

Volltextzugriff (PDF)

Sepsis Increases Lung Glutamine Synthetase Expression in the Tumor-Bearing Host

The Journal of surgical research, 1998-07, Vol.78 (1), p.18-22

1998

Volltextzugriff (PDF)

Abstract 2129: Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2129-2129

2023

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(58)
Tagungsberichte
(1)

Sprache

Englisch
(59)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers

Effect of itraconazole on the pharmacokinetics of faldaprevir in healthy subjects

Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors

Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing

P740 PHARMACOKINETICS OF FALDAPREVIR IN HEALTHY SUBJECTS FOLLOWING CO-ADMINISTRATION WITH ITRACONAZOLE

The Herpes Simplex Virus vhs Protein Induces Endoribonucleolytic Cleavage of Target RNAs in Cell Extracts

HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice

O65 HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN

697P Open-label, phase I, dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab

Prognosis and survival in patients with gastrointestinal tract carcinoid tumors

Picornavirus Internal Ribosome Entry Site Elements Target RNA Cleavage Events Induced by the Herpes Simplex Virus Virion Host Shutoff Protein

1236 MECHANISMS OF ISOLATED UNCONJUGATED HYPERBILIRUBINEMIA INDUCED BY THE HCV NS3/4A PROTEASE INHIBITOR BI201335

[36] Herpes simplex virus vhs protein

542P Ezabenlimab (BI 754091) monotherapy in patients (pts) with advanced solid tumours

Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial

1243TiPPhase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L)1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors

Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir

Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors

Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer

An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors

PHARMACOGNOSTICAL, ANTIMICROBIAL AND LAXATIVE STUDY OF SCORZONERA UNDULATA IN LIBYA

Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors

Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors

Sepsis Increases Lung Glutamine Synthetase Expression in the Tumor-Bearing Host

Abstract 2129: Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors

Suchergebnisse filtern